• Home
  • News
  • Portfolio News
  • Akston Biosciences Announces Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate

Akston Biosciences Announces Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate

09Jul

Akston Biosciences Announces Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate

Portfolio News

Today, Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced positive results from a 60-subject, open-label, Phase I trial of AKS-452, its protein subunit, room temperature stable, COVID-19 vaccine candidate. Read more >>

Share this post

Related Posts

27Jun

Wasabi Debuts U.S. West Coast New Data Center in Hillsboro, Oregon

Opens New Hot Cloud Storage Opportunities For US West Coast and Pac Rim Companies While Providing Direct Connection to One... read more
22Mar

Candidly and intellicents Announce Partnership to Help Workers Tackle Student Loan Debt

Candidly, the leading AI-driven student debt and savings optimization platform, announced today a partnership with intellicents to bring Candidly’s student... read more
03Oct

This New Canned Orange Wine Will Get Me Through Fall

So when I got an opportunity to sample the new Archer Roose limited release skin-macerated canned orange wine, I said... read more
27Sep

Zylö Therapeutics Closes $4 Million Series A Financing

Zylö Therapeutics Inc., dedicated to developing a transformational topical delivery platform, announced that on September 21, 2019, it effected a... read more
23Mar

Star-Studded Spirits

Mega-watt celebrities, From Elizabeth Banks to Dwayne “The Rock” Johnson, Have Launched Their Own Drink Lines. Raise a Glass to... read more
02Aug

Platelet BioGenesis Moves to New Cambridge Lab Space to Support Continued Growth

Platelet BioGenesis (PBG), the leader in the production of functional human platelets (PLTs+™) from stem cells and the development of... read more
06Sep

Credit union adopts digital piggy bank benefit for student loan repayment

A latte costs $4.50 — round it up to $5 even and that extra 50 cents can help employees pay... read more
14Nov

Five blind, visually-impaired people receive breakthrough electronic glasses that restore vision

Five blind and visually-impaired people can now see with the help of their new glasses from eSight. Read more >> read more
26May

Is The “Tinder-fication” Of Online Dating Over? S’More Thinks So, And Has The Data To Back It Up

New data gathered by the dating app company S’More suggests that their unique approach to online dating — one that... read more
08Sep

CytoAgents Announces Appointment of New Chief Medical Officer

CytoAgents, Inc., a clinical-stage therapeutics company developing a safe, effective treatment (CTO1681) for Cytokine Release Syndrome (CRS), today announced that... read more